BofA initiated coverage of Catalyst Pharmaceuticals with a Buy rating and $23 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CPRX:
- Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
- Catalyst Pharmaceuticals sees FY24 revenue $455M-$475M, consensus $463.19M
- Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals reports Q4 adjusted EPS 56c, consensus 26c
- Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE